Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Shaker Investments LLC OH

Shaker Investments LLC OH lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 75,326 shares of the biopharmaceutical company’s stock after purchasing an additional 8,249 shares during the period. Halozyme Therapeutics accounts for about 1.5% of Shaker Investments LLC OH’s holdings, making the stock its 21st biggest holding. Shaker Investments LLC OH’s holdings in Halozyme Therapeutics were worth $3,601,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC boosted its stake in Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares in the last quarter. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares in the last quarter. Diversify Advisory Services LLC grew its holdings in Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 418 shares during the period. Sheaff Brock Investment Advisors LLC raised its position in Halozyme Therapeutics by 7.7% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 507 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in Halozyme Therapeutics by 0.5% in the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock valued at $6,367,000 after acquiring an additional 561 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $57.34 on Tuesday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market capitalization of $7.30 billion, a price-to-earnings ratio of 18.99, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a 50 day simple moving average of $51.73 and a 200-day simple moving average of $54.42. Halozyme Therapeutics, Inc. has a 52-week low of $34.36 and a 52-week high of $65.53.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HALO. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.